
Nexstim Plc: Managers’ Transactions, Hannula
Company Announcement, Helsinki, 22 May 2023 at 10:35 AM(EEST)
Nexstim Plc: Managers’ Transactions, Hannula
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows:
Person subject to the notification requirement
Name: Henri Hannula
Position: Other senior manager
Issuer: Nexstim Oyj
LEI: 743700S7ZI0LNMHZ6Y27
Notification type: INITIAL NOTIFICATION
Reference number: 32077/5/6
____________________________________________
Transaction date: 2023-05-18
Outside a trading venue
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Name of the instrument: 2023A
Nature of transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 15796 Unit price: 0 EUR
Aggregated transactions (1):
Volume: 15796 Volume weighted average price: 0 EUR
____________________________________________
Transaction date: 2023-05-18
Outside a trading venue
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Name of the instrument: 2023B
Nature of transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 15550 Unit price: 0 EUR
Aggregated transactions (1):
Volume: 15550 Volume weighted average price: 0 EUR
____________________________________________
Transaction date: 2023-05-18
Outside a trading venue
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Name of the instrument: 2023C
Nature of transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 15303 Unit price: 0 EUR
Aggregated transactions (1):
Volume: 15303 Volume weighted average price: 0 EUR
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
The Company’s Certified Advisor is Erik Penser Bank.
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Schweiter strengthens its Core Materials business – acquisition of JMB Wind Engineering completed1.6.2023 06:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Schweiter strengthens its Core Materials business – acquisition of JMB Wind Engineering completed Schweiter Technologies is increasing its 40% minority holding by taking over the remaining 60% of the stock. The agreement to purchase the rest of the shares in JMB Wind Engineering (“JMB”) has been signed and completed, further strengthening the Core Materials business of 3A Composites. Steinhausen, 1 June 2023 – JMB (www.jmbwind.com) is a leading developer and producer of core material kits – primarily balsa and PET products for wind turbines. It is headquartered in Goleniów, Poland and has subsidiaries in Poland, Portugal and Brazil. The company acquired has approximately 430 employees and achieved sales of around EUR 70 million in the 2022 business year. Schweiter Technologies acquired a 40% share of JMB in 2021 to establish a strategic partnership with a leading European kitting company. The acquisition of the remaining holding in JMB and the
SET Launches New Trading System Leveraging Nasdaq Technology to Meet End-to-End Investment Needs1.6.2023 04:00:00 CEST | Press release
BANGKOK, Thailand and NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- The Stock Exchange of Thailand (SET) has successfully launched its new trading system, together with market data distribution and market surveillance systems, based on Nasdaq (Nasdaq: NDAQ) technology. All systems are running seamlessly and operating at full efficiency in line with international standards and best practice. This newly developed state-of-the-art solution will support increasing transaction volumes and a variety of innovative investment products, whilst further enhancing the trust and integrity of the market. This implementation marks a significant milestone in the ongoing development of the modern Thai capital market, established to promote economic growth and stability, and to develop people’s standard of living. Today, SET has the highest liquidity among ASEAN exchanges, a position the exchange has held for more than 10 years. In 2022, capital raised through IPOs totaled 3.46 billion USD, the highest in
Havila Kystruten AS: Sustainability Report 2022 and Human Rights and Transparency Act 20221.6.2023 00:00:32 CEST | Press release
Please find attaced the - Sustainability Report 2022 - Human Rights and Transparency Act 2022 Attachments HKY - Sustainability Report 2022HKY Human Rights and Transparency Act 2022
Santhera Publishes Annual Report 202231.5.2023 23:50:39 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May31, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the publication of its Annual Report 2022 with fully audited results for the year ended December 31, 2022. Santhera’s Annual Report 2022 provides comprehensive and detailed information on the Company, its strategy, business, financial performance, governance and compensation in 2022, and confirms the preliminary unaudited 2022 annual results which were published on April 27, 2023. The Annual Report 2022 is available for download on the Company’s website at www.santhera.com/financial-reports. Corporate calendar June 27, 2023 Annual General Meeting About Santhera Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. The Company has an exclusive license for all indications worldwide to vamor
Havila Kystruten AS: Årsrapport 2022 med Revisors rapport31.5.2023 23:30:41 CEST | Pressemelding
Vedlagt følger selskapets årsrapport og revisors rapport for 2022. Ordinær generalforsamling holdes 16. juni 2023. Innkalling og agenda sendes 2. juni 2023. Kontakter: Administrerende direktør Bent Martini, +47 905 99 650 Finansdirektør Arne Johan Dale, +47 909 87 706 Vedlegg HKY_2022_Annual Report